It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesized and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
We are excited to present our ability to produce large (up to 350 mg) batches of high quality monomeric, wild type, human alpha synuclein (αSyn) protein. Our αSyn has excellent batch-to-batch reproducibility, that displays no self-seeding in Seed Aggregation Assays (SAAs), including Real-Time Quaking-Induced Conversion (RT-QuIC) assays, enabling reliable analysis of CSF samples.
To support these claims, data from Sygnature’s internal team and two world-renowned SAA-expert laboratories are presented below.
To discuss your particular requirements and to get a quote for a custom batch ofαSyn please get in touch.
Figure 1: Reduced SDS PAGE of three separate αSyn batches (A – C) produced at Sygnature Discovery. Note, the αSyn tends to run higher than its actual 14kDa with respect to the molecular weight markers in the first lane.
Some lower molecular weight species are typically observed, and occasionally higher molecular weight species are present (e.g Figure 1 C). Neither impact performance in SAAs.
We are also able to produce various mutant versions of αSyn (Figure 2).
Figure 2: Portfolio of available αSyn variants (based on wild-type UniProt P37840). All are produced in E. coli, purified to the same high standard, and supplied without affinity tags. Other mutants or tagged versions can be discussed upon request.
Background to αSyn
As both a therapeutic target and a key biomarker, α-synuclein (αSyn) sits at the center of efforts to better understand, diagnose and treat neurodegenerative disorders. Its involvement in diseases such as Parkinson’s disease and Dementia with Lewy bodies (DLB) has made αSyn a major focus for drug discovery, biomarker development and translational research.
Under normal conditions, αSyn is a small, intrinsically disordered 14 kDa protein found in neurons. In Parkinson’s disease and related synucleinopathies, however, αSyn can misfold and aggregate into the characteristic fibrils associated with neuronal dysfunction and cell death. For an overview of αSyn protein and its role in disease, please refer to our mini review article here.
As interest in αSyn-based therapeutics and diagnostic approaches continues to grow, access to high-quality, well-characterized αSyn reagents has become increasingly important.
The Challenge
Production of highly pure, stable monomeric αSyn protein (Uniprot P37840) to support SAAs, which include the Real-Time Quaking-Induced Conversion (RT-QuIC) assays, has proved to be incredibly difficult to achieve. The requirements for the αSyn to support these assays are that it should be:
Monomeric
Stable, and does not self-seed or self-aggregate throughout the time course of the assay
Gives a good signal window in SAAs that allows clear discrimination of patient test samples that either contain or do not contain pathological αSyn
Has consistent batch-to-batch performance in SAAs
Ideally large (>100mg) batches of purified protein
Although αSyn is available from multiple commercial suppliers, researchers continue to report batch-to-batch variability that can compromise the consistency and reliability of data from SAAs. Indeed, Oliviera et al., 2026 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) made this statement:
“Furthermore, commercially available aSyn proteins yielded inconsistent and suboptimal results, and scaling up production posed significant technical and logistical challenges. In response, MJFF launched a large-scale effort to develop affordable, high-quality, commercially available aSyn SAA substrate through a precompetitive collaboration across industry, protein manufacturers, academic SAA experts, and commercial distributors– all for the benefit of the broader research community”
Producing high-quality recombinant αSyn is particularly challenging because the protein can undergo non-specific conversion and aggregation if not carefully handled and controlled during purification.
We have observed cases where a recombinant αSyn preparation looked pure on SDS PAGE gel, had the exact expected mass on intact mass spectrometry (with no contaminant peaks or modifications), was monomeric on analytical size-exclusion chromatography with multi-angle light scattering (SEC-MALS) and Flow Induced Dispersion Analysis (FIDA), yet obviously still contained, undetectable trace levels of oligomeric αSyn that were unfortunately sufficient to initiate self-seeding in an RT-QuIC assay (Figure 3).
Figure 3: RT-QuIC assay data (repeats of 3 spiked and 8 unspiked control runs) with a poor batch of αSyn substrate that displays spontaneous aggregation in unspiked control (grey) even though a good signal is still observed with DLB Brain homogenate (blue).
Detection of these undesired oligomers is impossible with current biophysical techniques, the only true test being validation in the end use SAA or desired application. This purification challenge is discussed in Stephens et al., 2020 with one solution presented by Al-Azzawi et al., 2025 to purify αSyn from the periplasmic fraction. However, this periplasmic route is not optimal as a method to produce the large amounts of αSyn generally required to support RT-QuIC assays.
Our Solution
Production of monomeric wild type human alpha synuclein
Within the Protein and Structure department at Sygnature Discovery, we have been purifying wild type and mutant versions of αSyn for different clients for several years, using either E. coli or mammalian expression hosts, and a variety of purification protocols. Our clients routinely return for resupplies for their assays which is a testament to the quality and batch-to-batch consistency of the αSyn we produce.
Building on this experience, for the last few years we have been running a project supported by The MJFF to optimize the production of monomeric wild type human αSyn. The ultimate goal of the project is to produce large (≥4 gram) batches of αSyn to make available as a global resource to reduce variability in data obtained between groups working on Parkinsons Disease.
During this project we have run hundreds of experiments to refine cell culture and protein purification protocols. In order to validate and to confirm that the αSyn produced is fit for purpose the trial batches have been tested in RT-QuIC assays by Christina Orru in the Caughey lab at the NIH/NIAID and Graham Fairfoul in the Barria (formerly Green) lab at The University of Edinburgh.
To address the challenges associated with producing reliable αSyn reagents, Sygnature Discovery has developed a robust expression and purification process for wild-type human αSyn in E. coli. This process routinely delivers:
Up to 350mg batches of αSyn
>90% pure protein – Figure 1 (however our data suggests that purity is NOT critical for performance in RT-QuIC assays)
Consistent batch-to-batch reproducibility in terms of yield, purity and most importantly performance in RT-QuIC assays
αSyn with remarkable stability in RT-QuIC assays (≥150 hours showing no spontaneous self-aggregation) – Figure 4 a to c
Excellent assay windows in RT-QuIC assays with challenging patient-derived samples – Figure 4 a to c
Figure 4a: RT-QuIC assay data (each in triplicate) performed by the NIH/NIAID with αSyn negative control (left) CBD (Corticobasal degeneration) brain homogenates (BH) showing no spontaneous seeding with αSyn >150 hours, (right) rapid amplification of aggregated αSyn from a DLB (Dementia with Lewy bodies) brain homogenates (BH) sample and overall good discrimination between a αSyn-negative and -positive brain sample.Figure 4b: RT-QuIC assay data (each in triplicate) performed by the NIH/NIAID with negative Cerebral Spinal Fluid (CSF) control (left) showing no spontaneous seeding with αSyn >50 hours and (middle) a rapid detection of low levels of aggregated αSyn in CSF spiked with a Parkinsons Disease patient (PD) Brain Homogenate and (right) with DLB Brain homogenate.Figure 4c: RT-QuIC assay data performed by the University of Edinburgh with DLB Brain homogenate (blue) and unspiked control (grey) and with unspiked artificial CSF control (green) and spiked artificial CSF (yellow). Both experiments show no spontaneous aggregation of the αSyn in the control unspiked experiments over 120 hours (grey and green) and then excellent ThT fluorescence assay signal with the spiked samples (blue and yellow).
Figure 4 a-c data was presented by Polinski et al., 2025 at the AD/PD conference.
In addition, based on the protocols described in Polinski et al., 2018, we have produced Pre-Formed Fibrils (PFFs) using our in-house αSyn to test and compare various batches of monomeric αSyn. Figure 5 and 6
Figure 5: Seed aggregation assay with in-house αSyn PFFs. Left: monomers only – no self aggregation of 8 separate batches αSyn observed over 50 hours. Right: monomers with 8 separate batches of αSyn – all displaying good aggregation signal with ThTFigure 6: Seed aggregation assay with in-house αSyn PFFs and 3 different batches of monomeric αSyn.
In Summary
At Sygnature Discovery, we support Parkinson’s disease and broader synucleinopathy research with the production of high-quality recombinant αSyn for Seed Aggregation Assays (SAAs), including RT-QuIC, PFF production, drug screening and other end use applications.
We routinely produce large (up to 350mg) batches of high quality monomeric, wild-type, human alpha synuclein (αSyn) protein with the quality, consistency and performance required for demanding assay applications.
If required, we also have experience producing
mutant or tagged forms of αSyn
Other proteins involved in neurodegenerative diseases
Whether you are developing diagnostics, investigating disease mechanisms, or advancing novel Parkinson’s disease therapeutics, our team can help provide the αSyn reagents needed to support your research. Please don’t hesitate to get in touch to discuss your project requirements.
Al-Azzawi, Z. A. M., Silver, N. R. G., Mehra, S., Niu, S., Situ, C., Luo, W., Shlaifer, I., Ingelsson, M., Hyman, B. T., Trempe, J.-F., Durcan, T. M., Watts, J. C., & Fon, E. A. (2025). α-Synuclein purification significantly impacts seed amplification assay performance and consistency. Acta Neuropathologica Communications, 13(1), 225. https://doi.org/10.1186/s40478-025-02151-4
Polinski, N. K., Volpicelli-Daley, L. A., Sortwell, C. E., Luk, K. C., Cremades, N., Gottler, L. M., Froula, J., Duffy, M. F., Lee, V. M. Y., Martinez, T. N., & Dave, K. D. (2018). Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents. Journal of Parkinson’s Disease, 8(2), 303–322. https://doi.org/10.3233/JPD-171248
Stephens, A. D., Matak-Vinkovic, D., Fernandez-Villegas, A., & Kaminski Schierle, G. S. (2020). Purification of Recombinant α-synuclein: A Comparison of Commonly Used Protocols. Biochemistry, 59(48), 4563–4572. https://doi.org/10.1021/acs.biochem.0c00725
Oliveira, L. M. A., Frasier, M., Hutten, S, J. (2026). Collaborative action for biomarker breakthroughs: Validating α-synuclein seed amplification assays in Parkinson’s disease. Journal of Parkinson’s Disease, Special Issue: Open Science in Parkinson’s Research, 1 – 7. https://doi.org/10.1177/1877718X261431949
Nicole K. Polinski, Richard Mott, Anna Valentine, Graham Fairfoul, Marcelo Barria Matus, Alison Green, Christina D Orrú, Byron Caughey, Jonathan Jones,Panos Kopsiaftis, Matthew Biggs, Robert Cleverley, Zoe Arnott, Elisia Clark, Gloria Thakuria, Jamie Eberling (2025)
The Michael J. Fox Foundation’s efforts to develop specialized alpha-synuclein monomeric protein for the alpha-synuclein seed amplification assay
Poster presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders